Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N-diethyl-2-[(2-thienylcarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide is an experimental small molecule belonging to the class of thiophene carboxamides. It has a molecular formula of C18H22N2O2S2 and a molecular weight of approximately 362.51 g/mol[1][4][5]. The compound is not approved for medical use in any jurisdiction and has no known clinical indications or completed clinical trials[1]. It is primarily used as a research tool and has been identified as a potent inhibitor of kinesin-like protein 1 (KIF11), which plays an essential role in mitotic spindle formation during cell division[7]. Its mechanism suggests potential utility in cancer research or other areas involving cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N,N-diethyl-2-[(2-thienylcarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide.